# 摘要

| Ref | Title | Summary |
| --- | --- | --- |
| [^1] | [Supervised machine learning for microbiomics: bridging the gap between current and best practices](https://arxiv.org/abs/2402.17621) | 该研究通过分析大量期刊文章，总结了监督机器学习在微生物组学中的现有实践，探讨了实验设计方法的优缺点，并提出了如何避免常见实验设计缺陷的指导。 |
| [^2] | [Learning a Patent-Informed Biomedical Knowledge Graph Reveals Technological Potential of Drug Repositioning Candidates.](http://arxiv.org/abs/2309.03227) | 本研究提出了一种使用药物专利和生物医学数据库相结合的方法，识别具有技术潜力和科学证据的药物再定位候选物。通过构建科学的生物医学知识图谱和基于专利的生物医学知识图谱，我们可以综合分析多种信息源，为药物再定位研究提供新的视角。 |

# 详细

[^1]: 用于微生物组学的监督机器学习：弥合当前和最佳实践之间的差距

    Supervised machine learning for microbiomics: bridging the gap between current and best practices

    [https://arxiv.org/abs/2402.17621](https://arxiv.org/abs/2402.17621)

    该研究通过分析大量期刊文章，总结了监督机器学习在微生物组学中的现有实践，探讨了实验设计方法的优缺点，并提出了如何避免常见实验设计缺陷的指导。

    

    机器学习（ML）将加速临床微生物组学创新，如疾病诊断和预后。这将需要高质量、可重现、可解释的工作流程，其预测能力达到或超过监管机构对临床工具设定的高门槛。我们通过深入分析2021-2022年发表的100篇同行评议的期刊文章，捕捉了当前将监督ML应用于微生物组学数据的实践的一个快照。我们采用数据驱动方法，引导讨论各种实验设计方法的优点，包括关键考虑因素，如如何减轻小数据集大小的影响同时避免数据泄漏。我们进一步提供关于如何避免可能损害模型性能、可信度和可重复性的常见实验设计缺陷的指南。讨论附有一个互动在线教程。

    arXiv:2402.17621v1 Announce Type: cross  Abstract: Machine learning (ML) is set to accelerate innovations in clinical microbiomics, such as in disease diagnostics and prognostics. This will require high-quality, reproducible, interpretable workflows whose predictive capabilities meet or exceed the high thresholds set for clinical tools by regulatory agencies. Here, we capture a snapshot of current practices in the application of supervised ML to microbiomics data, through an in-depth analysis of 100 peer-reviewed journal articles published in 2021-2022. We apply a data-driven approach to steer discussion of the merits of varied approaches to experimental design, including key considerations such as how to mitigate the effects of small dataset size while avoiding data leakage. We further provide guidance on how to avoid common experimental design pitfalls that can hurt model performance, trustworthiness, and reproducibility. Discussion is accompanied by an interactive online tutorial th
    
[^2]: 学习基于专利的生物医学知识图谱揭示药物再定位候选物的技术潜力

    Learning a Patent-Informed Biomedical Knowledge Graph Reveals Technological Potential of Drug Repositioning Candidates. (arXiv:2309.03227v1 [cs.AI])

    [http://arxiv.org/abs/2309.03227](http://arxiv.org/abs/2309.03227)

    本研究提出了一种使用药物专利和生物医学数据库相结合的方法，识别具有技术潜力和科学证据的药物再定位候选物。通过构建科学的生物医学知识图谱和基于专利的生物医学知识图谱，我们可以综合分析多种信息源，为药物再定位研究提供新的视角。

    

    药物再定位是一种发现现有药物新治疗用途的有前途的策略，近年来在计算科学文献中使用生物医学数据库进行了广泛探索。然而，药物再定位候选物的技术潜力经常被忽视。本研究提出了一种新的方法，综合分析药物专利和生物医学数据库等多种信息源，识别具有技术潜力和科学证据的药物再定位候选物。首先，我们构建了一个科学的生物医学知识图谱（s-BKG），包括来自生物医学数据库的药物、疾病和基因之间的关系。我们的方法涉及识别在s-BKG中与目标疾病关联有限但在空间上紧密相邻的药物作为潜在的药物候选物。然后，我们通过添加药物专利信息构建了一个基于专利的生物医学知识图谱（p-BKG）。

    Drug repositioning-a promising strategy for discovering new therapeutic uses for existing drugs-has been increasingly explored in the computational science literature using biomedical databases. However, the technological potential of drug repositioning candidates has often been overlooked. This study presents a novel protocol to comprehensively analyse various sources such as pharmaceutical patents and biomedical databases, and identify drug repositioning candidates with both technological potential and scientific evidence. To this end, first, we constructed a scientific biomedical knowledge graph (s-BKG) comprising relationships between drugs, diseases, and genes derived from biomedical databases. Our protocol involves identifying drugs that exhibit limited association with the target disease but are closely located in the s-BKG, as potential drug candidates. We constructed a patent-informed biomedical knowledge graph (p-BKG) by adding pharmaceutical patent information. Finally, we d
    

